|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 175,200.00 KRW | +1.21% |
|
-4.58% | +1.64% |
| 07-07 | Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA | MT |
| 07-03 | South Korean Shares Jump on Bargain-Hunting, Chip Stock Gains | MT |
Company Valuation: Celltrion, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27,592,583 | 23,000,359 | 27,970,378 | 40,365,453 | 39,602,284 | 40,178,131 | - | - |
| Change | - | -16.64% | 21.61% | 44.32% | -1.89% | 1.45% | - | - |
| Enterprise Value (EV) 1 | 27,117 | 23,236 | 29,280 | 41,531 | 42,173 | 42,220 | 41,606 | 40,868 |
| Change | - | -14.31% | 26.01% | 41.84% | 1.55% | 0.11% | -1.45% | -1.77% |
| P/E | 47.2x | 41.6x | 53.7x | 91.7x | 38.8x | 27.1x | 24x | 20.9x |
| PBR | 6.87x | 5.34x | 2.46x | 2.2x | 2.32x | 2.21x | 2.03x | 1.87x |
| PEG | - | -9.54x | -20.3x | -2.1x | 0x | 0.6x | 1.9x | 1.4x |
| Capitalization / Revenue | 14.6x | 10.1x | 12.9x | 11.3x | 9.51x | 7.55x | 6.5x | 5.83x |
| EV / Revenue | 14.3x | 10.2x | 13.5x | 11.7x | 10.1x | 7.93x | 6.73x | 5.93x |
| EV / EBITDA | 27.9x | 26.6x | 32.6x | 45.6x | 29x | 19.9x | 16.9x | 14.7x |
| EV / EBIT | 36x | 35.9x | 44.9x | 84.4x | 36.1x | 23.4x | 19.4x | 16.6x |
| EV / FCF | 46x | -211x | 89.5x | 54.2x | 78.4x | 33.8x | 31.9x | 28x |
| FCF Yield | 2.17% | -0.47% | 1.12% | 1.85% | 1.28% | 2.96% | 3.14% | 3.57% |
| Dividend per Share 3 | 628.9 | - | 436.1 | 686.8 | 714.3 | 736 | 799.7 | 860.4 |
| Rate of return | 0.38% | - | 0.25% | 0.4% | 0.41% | 0.42% | 0.46% | 0.49% |
| EPS 3 | 3,515 | 3,362 | 3,273 | 1,873 | 4,438 | 6,476 | 7,308 | 8,402 |
| Distribution rate | 17.9% | - | 13.3% | 36.7% | 16.1% | 11.4% | 10.9% | 10.2% |
| Net sales 1 | 1,891 | 2,284 | 2,176 | 3,557 | 4,162 | 5,321 | 6,181 | 6,890 |
| EBITDA 1 | 972.1 | 873.6 | 897.2 | 910.3 | 1,456 | 2,120 | 2,468 | 2,787 |
| EBIT 1 | 753.9 | 647.2 | 651.5 | 492 | 1,168 | 1,807 | 2,148 | 2,467 |
| Net income 1 | 575.1 | 533.2 | 535.6 | 422.7 | 1,030 | 1,484 | 1,698 | 1,951 |
| Net Debt 1 | -475.5 | 235.5 | 1,310 | 1,165 | 2,571 | 2,041 | 1,427 | 689.5 |
| Reference price 3 | 166,042.75 | 139,979.07 | 175,736.96 | 171,703.30 | 172,380.95 | 175,200.00 | 175,200.00 | 175,200.00 |
| Nbr of stocks (in thousands) | 166,178 | 164,313 | 159,160 | 235,088 | 229,737 | 229,327 | - | - |
| Announcement Date | 2/16/22 | 3/3/23 | 2/29/24 | 2/25/25 | 2/4/26 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.05x | 7.93x | 19.91x | 0.42% | 26.76B | |
| 35.38x | 6.18x | 19.12x | 0.93% | 50.73B | |
| -23.4x | 342.07x | -22.1x | -.--% | 39.73B | |
| 25.29x | 2.8x | 12.09x | -.--% | 34.69B | |
| 45.73x | 4.51x | 28.9x | -.--% | 33.21B | |
| 31.75x | 5.12x | 23.32x | -.--% | 15.37B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.78B | |
| 23.74x | 1.89x | 11.45x | -.--% | 12.85B | |
| -33.62x | 128.84x | -36.68x | -.--% | 12.11B | |
| Average | 17.32x | 55.71x | 7.22x | 0.27% | 26.58B | |
| Weighted average by Cap. | 19.65x | 67.11x | 9.15x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- A068270 Stock
- Valuation Celltrion, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
